GMP-grade manufacturing and quality control of a non-virally engineered advanced therapy medicinal product for personalized treatment of age-related macular degeneration
Published inBiomedicines, vol. 10, no. 11, 2777
Publication date2022-11-01
First online date2022-11-01
Abstract
Keywords
- Personalized medicine
- Autologous
- Regenerative medicine
- Cell product
- Cell therapy
- Advanced Therapy Medicinal Product (ATMP)
- Good Manufacturing Practice (GMP)
- Quality control
- Non-viral gene therapy
- Age-related macular degeneration (AMD)
- Iris pigment epithelial cells (IPE)
Research group
Funding
- European Commission - Transposon-based, targeted ex vivo gene therapy to treat age-related macular degeneration (AMD) [305134]
Citation (ISO format)
KROPP, Martina et al. GMP-grade manufacturing and quality control of a non-virally engineered advanced therapy medicinal product for personalized treatment of age-related macular degeneration. In: Biomedicines, 2022, vol. 10, n° 11, p. 2777. doi: 10.3390/biomedicines10112777
Main files (1)
Article (Published version)
Identifiers
- PID : unige:165332
- DOI : 10.3390/biomedicines10112777
- PMID : 36359296
Commercial URLhttps://www.mdpi.com/2227-9059/10/11/2777
ISSN of the journal2227-9059